110 related articles for article (PubMed ID: 1511423)
1. Variable expression of the interleukin-2 receptor alpha chain and MYC genes in lymphocytes from renal cell carcinoma patients treated with interleukin-2.
Hayat K; Finnegan M; Lee KA; Rees RC; Hancock BW; Goyns MH
Cancer Lett; 1992 Aug; 65(2):173-8. PubMed ID: 1511423
[TBL] [Abstract][Full Text] [Related]
2. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
Hermann GG
APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
[No Abstract] [Full Text] [Related]
3. Enhanced susceptibility of c-myc antisense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes.
Mizutani Y; Bonavida B; Fukumoto M; Yoshida O
J Immunother Emphasis Tumor Immunol; 1995 Feb; 17(2):78-87. PubMed ID: 7647959
[TBL] [Abstract][Full Text] [Related]
4. Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma.
Marumo K; Muraki J; Ueno M; Tachibana M; Deguchi N; Baba S; Jitsukawa S; Hata M; Tazaki H
Urology; 1989 Mar; 33(3):219-25. PubMed ID: 2784018
[TBL] [Abstract][Full Text] [Related]
5. In vivo activation of LAK cells during systemic IL-2 therapy.
Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
[No Abstract] [Full Text] [Related]
6. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
[TBL] [Abstract][Full Text] [Related]
7. Improved lymphocyte cytotoxicity against murine renal cell carcinoma.
Salup RR; Sicker DC; Ballou BT; Flack CE; Wolmark N; Hakala TR
J Urol; 1992 Feb; 147(2):491-5. PubMed ID: 1732630
[TBL] [Abstract][Full Text] [Related]
8. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
[TBL] [Abstract][Full Text] [Related]
9. In vivo distribution of recombinant interleukin-2-activated autologous lymphocytes administered by intra-arterial infusion in patients with renal cell carcinoma.
Morita T; Yonese Y; Minato N
J Natl Cancer Inst; 1987 Mar; 78(3):441-50. PubMed ID: 3102826
[TBL] [Abstract][Full Text] [Related]
10. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
[TBL] [Abstract][Full Text] [Related]
11. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
[TBL] [Abstract][Full Text] [Related]
12. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.
Schendel DJ; Gansbacher B
Cancer Res; 1993 Sep; 53(17):4020-5. PubMed ID: 8358731
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
15. Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2.
Hayat K; Rodgers S; Bruce L; Rees RC; Chapman K; Reeder S; Dorreen MS; Sheridan E; Sreenivasan T; Hancock BW
Eur J Cancer; 1991; 27(8):1009-14. PubMed ID: 1832884
[TBL] [Abstract][Full Text] [Related]
16. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2, killer cells and cancer therapy: an overview.
Parkinson DR; Lotzová E
Nat Immun Cell Growth Regul; 1990; 9(4):237-41. PubMed ID: 2215512
[No Abstract] [Full Text] [Related]
18. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte-conditioned medium in combination with interleukin-2 effectively induces antitumour autoimmunity by adoptive transfer of short activated killer (SHAK) cells.
Buer J; Hilse R; Dallmann I; Grosse J; Kirchner H; Zorn U; Hänninen EL; Franzke A; Duensing S; Poliwoda H
Cytokines Mol Ther; 1995 Mar; 1(1):39-46. PubMed ID: 9384662
[TBL] [Abstract][Full Text] [Related]
20. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
